These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34936548)

  • 1. Real-life golimumab persitence in patients with axial spondyloarthritis: post-hoc results of the prospective observational cohort study, GO-PRACTICE.
    Goupille P; Bertin P; Tubach F; Lespessailles E; Harid N; Sequeira S; Fayette JM; Fautrel B; Flipo RM
    Clin Exp Rheumatol; 2022 Jul; 40(7):1352-1360. PubMed ID: 34936548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study.
    Flipo RM; Tubach F; Goupille P; Lespessailles E; Harid N; Sequeira S; Bertin P; Fautrel B
    Clin Exp Rheumatol; 2021; 39(3):537-545. PubMed ID: 32896246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
    Govoni M; Batalov A; Boumpas DT; D'Angelo S; De Keyser F; Flipo RM; Kellner H; Leroi H; Khalifa A
    Clin Exp Rheumatol; 2024 Mar; 42(3):642-650. PubMed ID: 37976120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
    Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
    Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.
    Athanassiou P; Kotrotsios A; Kallitsakis I; Bounas A; Dimitroulas T; Garyfallos A; Tektonidou MG; Vosvotekas G; Livieratos A; Petrikkou E; Katsifis G
    Qual Life Res; 2022 May; 31(5):1385-1399. PubMed ID: 34839451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Weinstein CLJ; Meehan AG; Lin J; Briscoe SD; Govoni M
    Clin Rheumatol; 2023 Dec; 42(12):3397-3405. PubMed ID: 37751000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
    Iannone F; Favalli EG; Caporali R; D'Angelo S; Cantatore FP; Sarzi-Puttini P; Foti R; Conti F; Carletto A; Gremese E; Cauli A; Ramonda R; Palermo A; Epis O; Priora M; Bergossi F; Frediani B; Salaffi F; Lopalco G; Cacciapaglia F; Marchesoni A; Biggioggiero M; Bugatti S; Balduzzi S; Carriero A; Corrado A; Bongiovanni S; Benenati A; Miranda F; Fracassi E; Perra D; Ferraccioli G; Lapadula G
    Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
    Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
    Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Iannone F; Santo L; Anelli MG; Bucci R; Semeraro A; Quarta L; D'Onofrio F; Marsico A; Carlino G; Casilli O; Cacciapaglia F; Zuccaro C; Falappone PC; Cantatore FP; Muratore M; Lapadula G
    Semin Arthritis Rheum; 2017 Aug; 47(1):108-114. PubMed ID: 28216195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.
    Michelena X; Zhao SS; Dubash S; Dean LE; Jones GT; Marzo-Ortega H
    Rheumatology (Oxford); 2021 Dec; 60(12):5795-5800. PubMed ID: 33502476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
    Michelsen B; Sexton J; Wierød A; Bakland G; Rødevand E; Krøll F; Kvien TK
    Semin Arthritis Rheum; 2020 Feb; 50(1):12-16. PubMed ID: 31358361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.
    Lubrano E; Perrotta FM; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
    J Rheumatol; 2018 Feb; 45(2):195-201. PubMed ID: 29419448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study.
    Gehin JE; Warren DJ; Syversen SW; Lie E; Sexton J; Loli L; Wierød A; Bjøro T; Kvien TK; Bolstad N; Goll GL
    Scand J Rheumatol; 2021 Nov; 50(6):445-454. PubMed ID: 33650469
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
    Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Cea-Calvo L; Sánchez-Alonso F; Sánchez-Jareño M; Jovani V; García-Magallón B; Martínez-González O; Campos-Fernández C; Manero J; Díaz-Torne C; Bohórquez C; Ros-Vilamajó I; Pérez-Vera Y; Castrejón I
    Musculoskeletal Care; 2023 Mar; 21(1):189-197. PubMed ID: 35996810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis.
    Paccou J; Flipo RM
    Drug Des Devel Ther; 2016; 10():2255-62. PubMed ID: 27468228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.